Steven N Lee Tran, OD
Optometrist · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Tran’s office at (408) 554-9830 to ask if they take your plan before you enroll.
California Medical Board record
Licence G12368 · Deceased
Licence status: Deceased · since 1966 · University of Southern California Keck School of Medicine.
Licensee is deceased.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$12,764 in 2024
Medicaid paid $12,764 for 397 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 182 | $10,388 |
| DETERMINATION REFRACTIVE STATE | 215 | $2,376 |
| 2024 | 397 | 2 | 27 | $12,764 |
| 2023 | 284 | 2 | 27 | $31 |
| 2022 | 201 | 2 | 33 | $71 |
| 2021 | 245 | 2 | 20 | $45 |
| 2020 | 86 | 2 | 19 | $0 |
| 2019 | 112 | 2 | 24 | $7 |
| 2018 | 85 | 2 | 22 | $0 |
See the largest Medicaid services in earlier years
2023
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 99 | $23 |
| DETERMINATION REFRACTIVE STATE | 185 | $8 |
2022
| DETERMINATION REFRACTIVE STATE | 165 | $50 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 36 | $20 |
2021
| DETERMINATION REFRACTIVE STATE | 192 | $45 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 53 | $0 |
2020
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 15 | $0 |
| DETERMINATION REFRACTIVE STATE | 71 | $0 |
2019
| DETERMINATION REFRACTIVE STATE | 98 | $7 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 14 | $0 |
2018
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 15 | $0 |
| DETERMINATION REFRACTIVE STATE | 70 | $0 |
Drugs they prescribed that Part D paid
$3,386
Pharmacies billed $3,386 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 77) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
57 generic and 20 brand-name prescriptions · $3,386 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cyclosporine | 19 | $2,431 | $128 |
| Ofloxacin | 35 | $547 | $16 |
| Erythromycin | 15 | $202 | $13 |
Year by year
| 2024 | 77 | 52 | 0% (0) | 26% | $3,386 |
| 2023 | 42 | 25 | 0% (0) | None | $2,201 |
| 2022 | 26 | None | 0% (0) | 54% | $5,638 |
| 2021 | 16 | 12 | 0% (0) | 69% | $7,141 |
| 2020 | 21 | None | 0% (0) | None | $9,158 |
| 2019 | 32 | 16 | 0% (0) | 53% | $13,397 |
| 2018 | 32 | 19 | 0% (0) | 75% | $15,925 |
| 2017 | 36 | 20 | 0% (0) | 75% | $15,411 |
| 2016 | 18 | None | 0% (0) | 78% | $6,410 |
| 2015 | 22 | 14 | 0% (0) | 59% | $7,339 |
| 2014 | 16 | None | 0% (0) | 81% | $5,227 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Erythromycin | 17 | $250 | $15 |
2019: 1 drug
| Restasis | 14 | $12,671 | $905 |
2018: 1 drug
| Restasis | 20 | $15,289 | $764 |
2017: 1 drug
| Restasis | 24 | $15,042 | $627 |
2016: 1 drug
| Restasis | 12 | $6,239 | $520 |
2015: 1 drug
| Restasis | 13 | $7,141 | $549 |
Money from drug and device companies
$17 in 2020
| 2020 | 1 | 1 | None | $17 |
| 2019 | 1 | 1 | None | $66 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Carl Zeiss Meditec | None Specified | $17 | 1 payment
|
See the published payment
| Carl Zeiss Meditec | Gift · 2020-05-14 | None Specified | $17 |
See earlier years (2019)
2019: $66
| Shire North American Group | Xiidra | $66 | 1 payment
|
Professional record
- NPI
- 1679626220
- Licence
- CA 12368California G12368: Deceased
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 710 Lawrence Expy, Optometry Dept #486, Santa Clara, CA, 95051
- NPI first listed
- 2007-01-18
- NPI last updated
- 2022-01-03
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.